ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2026
Assessment of Rebound in Cancer Diagnoses in California in 2022, by Stage, Sociodemographic Factors, and Rurality.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe reduction in cancer cases in 2020 has been attributed to missed diagnoses during the pandemic, yet no rebound occurred in 2021. We examined whether cancer rebounded in California in 2022.
methodsData on invasive tumors in California for 2001 to 2022 were obtained through the NCI Surveillance, Epidemiology, and End Results program. Expected cases for 2022 were calculated using joinpoint regression models based on trends from 2001 to 2021 (omitting 2020). We calculated the ratio of observed to expected (O/E) cases in 2022 and 95% confidence intervals (CI).
resultsThere was no overall difference in observed versus expected invasive tumors in California in 2022. However, lung cancer was 29% lower than expected in rural areas (O/E: 0.71; 95% CI, 0.39-0.95), uterine cancer was lower than expected in Los Angeles (O/E: 0.91; 95% CI, 0.86-0.96), and breast cancer was lower than expected in Greater California (O/E: 0.95; 95% CI, 0.90-0.98). Groups with more tumors observed than expected included unstaged colorectal cancer in Greater California (O/E: 1.54) and Los Angeles (O/E: 1.26), colorectal cancer among males (O/E: 1.12) and Asian Americans (O/E: 1.16) in the Greater Bay Area, localized melanoma in Greater California (O/E: 1.24), and prostate cancer among Hispanic males in Los Angeles (O/E: 1.24).
conclusionsOverall, observed invasive tumors did not differ from expected in California in 2022, but there was variation across demographic, regional, and clinical factors. The reduction in cancer cases in 2020 likely reflects multiple factors, including missed diagnoses and death due to competing causes. IMPACT: Continued close monitoring of cancer diagnoses is needed to inform cancer control strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.